CoChat

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Open access
Giles, F J, Abruzzese, E, Rosti, G, Kim, D-W, Bhatia, R, Bosly, A, Goldberg, S, Kam, G L S, Jagasia, M, Mendrek, W, Fischer, T, Facon, T, Dünzinger, U, Marin, D, Mueller, M C, Shou, Y, Gallagher, N J, Larson, R A, Mahon, F-X, Baccarani, M, Cortes, J, Kantarjian, H M · 2010 · Leukemia
Cited by 117

The DOI matches its Crossref record.

Abstract

Nilotinib is a highly selective Bcr–Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake and efflux properties, and thus patients may respond to one following failure of the other. An international phase II study of nilotinib was conducted in CML patients (39 chronic phase (CP), 21 accelerated phase (AP)) after failure of both imatinib and dasatinib. Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively. Complete hematological response and major cytogenetic response (MCyR) rates in CP were 79% and 43%, respectively. Of 17 evaluable patients with CML-AP, 5 (29%) had a confirmed hematological response and 2 (12%) a MCyR. The median time to progression has not yet been reached in CP patients. At 18 months 59% of patients were progression-free. Median overall survival for both populations has not been reached, and the estimated 18-month survival rate in CML-CP was 86% and that at 12 months for CML-AP was 80%. Nilotinib is an effective therapy in CML-CP and -AP following failure of both imatinib and dasatinib therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2010.110

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 117

Metadata

Authors
Giles, F. J., Abruzzese, E., Rosti, G., Kim, D.-W., Bhatia, R., Bosly, A., Goldberg, S., Kam, G. L. S., Jagasia, M., Mendrek, W., Fischer, T., Facon, T., Dünzinger, U., Marin, D., Mueller, M. C., Shou, Y., Gallagher, N. J., Larson, R. A., Mahon, F.-X., Baccarani, M., Cortes, J., & Kantarjian, H. M.
Venue
Leukemia
Published
2010-06-03
Volume
24
Issue
7
Pages
1299-1301
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2039531591
Cited by
117
References
0
FWCI
7.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. https://app.cochat.ai/papers/10.1038/leu.2010.110
The paper
Giles, F. J., Abruzzese, E., Rosti, G., Kim, D.-W., Bhatia, R., Bosly, A., Goldberg, S., Kam, G. L. S., Jagasia, M., Mendrek, W., Fischer, T., Facon, T., Dünzinger, U., Marin, D., Mueller, M. C., Shou, Y., Gallagher, N. J., Larson, R. A., Mahon, F.-X., . . . Kantarjian, H. M. (2010). Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. https://doi.org/10.1038/leu.2010.110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.